PREFER is a project which aims to create an Advanced Therapy Medicinal Product (ATMP) that is able to revascularize the tissues affected by such wounds, and by doing so, to heal them. The objective is to improve existing therapies for the healing of difficult wounds by developing an innovative product based on the combination of an extracellular matrix, autologous endothelial cells and growth factors to stimulate the formation of blood vessels and the regrowth of the skin epithelium. After having properly evaluated the efficacy of the therapy from a histological and functional point of view through in vitro and in vivo studies, the final aim of the project will be to obtain a combined ATMP product that can be clinically tested through phase I/II studies. At the end of the clinical trial, scheduled after the closure of the project, the product is expected to be marketed at a low cost thanks to the expansion of endothelial cells using NANT technology.
This project is funded by Programma Operativo del Fondo europeo di sviluppo regionale 2014-2020 del Friuli Venezia Giulia.
TOTAL BUDGET - TOTAL CONTRIBUTION
€ 1.102,085 - € 718.486,92
